RDIF and Landsteiner Scientific Ink Deal for Sputnik V COVID-19 Vaccine to Mexico
Posted on 09/10/2020
Revealed on September 9, 2020, the Russian Direct Investment Fund (RDIF) and Landsteiner Scientific pharmaceutical company have announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico. This is equivalent to around 25% of the Mexican population. RDIF claims the deliveries are expected to start in November 2020 subject to approval by Mexico’s regulators. Landsteiner Scientific was established in 1998 and is a vertically integrated, privately held pharmaceutical company headquartered in Mexico City.
According to the press release, “As part of the agreement with RDIF, Landsteiner Scientific as a partner of RDIF would distribute the vaccine in Mexico.
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on human adenoviral vectors platform. Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.com
On September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in one of the leading international medical journals The Lancet. Phase I and Phase II trials demonstrated no serious adverse events and a stable immune response in 100% of participants.
Post-registration clinical trials of Sputnik V vaccine involving 40,000 volunteers are currently ongoing. First results of these trials are expected to be published in October-November 2020.
Health safety of the human adenovirus vaccines has been proven by more than 75 international publications and 250 clinical trials showing greater safety track record of human adenoviral vectors versus novel unproven technologies such as monkey adenoviral vectors or mRNA.”